Novel therapies against autoimmune diseases and allergies


Exit 2015

SuppreMol is a biopharmaceutical company developing novel therapies for the treatment of autoimmune diseases and allergies. The company is a pioneer in therapeutic approaches using soluble Fc-gamma receptors (FcgRs). FcgRs are recombinant, autologous therapeutic proteins with specific immunoregulatory potential. The company is developing recombinant soluble Fc-gamma receptor IIB (FcgRIIB) for the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).

MIG invests in SuppreMol 2008
Exit 2015
Back to portfolio